Center-Authored Papers

Filters: Author is Li, Hongli  [Clear All Filters]
B
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM et al..  2015.  Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
C
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA et al..  2016.  RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.. British journal of haematology. Abstract
D
Danilov AV, Li H, Press OW, Shapira I, Swinnen LJ, Noy A, Reid E, Smith SM, Friedberg JW.  2016.  Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial.. Leukemia & lymphoma. :1-5.
F
Friedberg JW, Unger JM, Burack RW, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP et al..  2014.  R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.. British journal of haematology. Abstract
P
Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, De Rosa SC, McElrath MJ.  2010.  Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).. PloS one. 5(10):e13579. Abstract
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES et al..  2016.  US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(17):2020-+. Abstract
Puvvada SD, Stiff PJ, LeBlanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN et al..  2016.  Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.. British journal of haematology. 174(5):686-691. Abstract
Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox A-M et al..  2016.  A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.. Leukemia & lymphoma. 57(10):2359-2369. Abstract
S
Shulman N, Bellew M, Snelling G, Carter D, Huang Y, Li H, Self SG, McElrath MJ, De Rosa SC.  2008.  Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials.. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 73(9):847-56. Abstract
Stephens DM, Li H, Leblanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM.  2016.  Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(25):2997-3004. Abstract
T
Till BG, Li H, Bernstein SH, Fisher RI, Burack RW, Rimsza LM, Floyd JD, Dasilva MA, Moore DF, Pozdnyakova O et al..  2016.  Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.. British journal of haematology. 172(2):208-218. Abstract
Y
Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB et al..  2015.  SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(14):1601-8. Abstract